Paper Details

  1. Home
  2. Paper Details

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis.

Author: KandeelMahmoud

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Diabetic neuropathy (DN) is a common complication of diabetes mellitus (DM). This systematic review and meta-analysis assessed the benefits of using sodium-glucose co-transporter-2 inhibitors (SGLT2Is) to manage DN. The results suggest that SGLT2Is could be considered neuroprotective in patients with DN, possibly by improving nerve conduction velocity and reducing sympathetic nervous system activity.
Paper Details　
Original Abstract of the Article :
Diabetes mellitus (DM) is one of the leading causes of morbidity and mortality worldwide. DM patients with diabetic neuropathy (DN) usually present with distal pain, sensorimotor polyneuropathy, postural hypotension, or erectile dysfunction. They also may present with other nerve pathologies such as...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310020/

データ提供：米国国立医学図書館（NLM）

Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2Is): A New Hope for Diabetic Neuropathy

Diabetic neuropathy, a common complication of diabetes, can cause pain, numbness, and tingling in the limbs. This research reviews the outcomes of using sodium-glucose co-transporter 2 inhibitors (SGLT2Is) for the management of diabetic neuropathy. It investigates the potential benefits of these medications in improving nerve function and alleviating neuropathy symptoms. It's like discovering a new oasis in the desert that offers respite and nourishment for those suffering from the effects of a long and arduous journey.

SGLT2Is: A Promising Approach to Neuropathy Management

The meta-analysis reveals that SGLT2Is demonstrate moderate improvements in diabetic neuropathy manifestations, including nerve conduction velocity and clinical symptoms. The study also suggests that these medications may reduce sympathetic nervous system activity. It's like finding a hidden spring in the desert that not only provides water but also restores balance and promotes well-being.

Managing Diabetic Neuropathy

This research highlights the potential benefits of using SGLT2Is for the management of diabetic neuropathy. It encourages individuals with diabetes and neuropathy to discuss these treatment options with their healthcare provider to determine the best course of action. It's like ensuring that the caravan of camels has access to the best possible resources and guidance to navigate the treacherous desert of diabetic neuropathy.

Dr.Camel's Conclusion

This research suggests that SGLT2Is may offer a promising approach to the management of diabetic neuropathy, providing potential benefits for individuals with this debilitating complication.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-07-29
Further Info :

Pubmed ID

35899123

DOI: Digital Object Identifier

PMC9310020

Related Literature

Article Analysis
・Causes of carpal tunnel syndrome
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.